<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table3" position="float"><object-id pub-id-type="doi">10.7554/eLife.37294.012</object-id><label>Table 3.</label><caption><title>Tumor CNA burden determined by clinically approved sequencing panel is associated with overall survival in primary and metastatic tumors</title></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="3"><italic>Model</italic></th><th colspan="12" valign="top"><italic>Overall Survival</italic></th></tr><tr><th colspan="4" valign="top"><italic>Primary tumors</italic></th><th colspan="8" valign="top"><italic>Metastatic tumors</italic></th></tr><tr><th valign="top">HR</th><th colspan="2" valign="top">95%</th><th valign="top">P</th><th colspan="3" valign="top">HR</th><th colspan="3" valign="top">95%</th><th colspan="2" valign="top">P</th></tr></thead><tbody><tr><td colspan="13">Prostate Cancer<sup>*,&#8224;</sup></td></tr><tr><td>Univariate, tumor CNA burden, per 5%</td><td colspan="2">1.17</td><td>1.04, 1.31</td><td>0.007</td><td colspan="2">1.07</td><td colspan="3">1.01, 1.14</td><td colspan="3">0.020</td></tr><tr><td valign="bottom">Multivariable <break/>Tumor CNA burden, per 5% <break/>Mutation burden (per mutation)</td><td colspan="2">1.11 <break/>1.22</td><td>0.98, 1.26 <break/>1.12, 1.33</td><td>0.10 <break/>&lt;0.0001</td><td colspan="2">1.08 <break/>1.05</td><td colspan="3">1.02, 1.15 <break/>1.02, 1.08</td><td colspan="3">0.011 <break/>0.001</td></tr><tr><td valign="bottom">Multivariable <break/>Tumor CNA burden, per 5% <break/><italic>TP53</italic> CN loss or mutation</td><td colspan="2">1.17 <break/>4.12</td><td valign="bottom">1.04, 1.31 <break/>2.02, 8.41</td><td valign="bottom">0.007 <break/>&lt;0.0001</td><td colspan="2" valign="top">1.06 <break/>1.24</td><td colspan="3" valign="top">1.00, 1.13 <break/>0.76, 2.02</td><td colspan="3" valign="top">NS (0.069) <break/>NS (0.4)</td></tr><tr><td valign="bottom">Multivariable <break/>Tumor CNA burden, per 5% <break/> <italic>RB1</italic> CN loss or mutation</td><td colspan="2">1.15 <break/>3.24</td><td>1.02, 1.30 <break/>0.70, 14.98</td><td valign="bottom">0.026 <break/>NS (0.13)</td><td colspan="2" valign="bottom">1.06 <break/>1.68</td><td colspan="3" valign="bottom">0.99, 1.13 <break/>0.94, 2.99</td><td colspan="3" valign="bottom">NS (0.091) <break/>NS (0.080)</td></tr><tr><td valign="bottom">Multivariable <break/>Tumor CNA burden, per 5% <break/><italic>PTEN</italic> CN loss or mutation</td><td colspan="2">1.17 <break/>2.38</td><td>1.04, 1.32 <break/>1.03, 5.51</td><td valign="bottom">0.008 <break/>0.042</td><td colspan="2" valign="top">1.07 <break/>1.15</td><td colspan="3" valign="top">1.01, 1.14 <break/>0.70, 1.89</td><td colspan="3" valign="top">0.023 <break/>NS (0.6)</td></tr><tr><td colspan="13">Pan- Cancer</td></tr><tr><td>Univariate, tumor CNA burden, per 5%<sup>&#8225;&#167;</sup></td><td colspan="2">1.04</td><td>1.02, 1.05</td><td>&lt;0.0001</td><td colspan="2">1.02</td><td colspan="5">1.01, 1.03</td><td>0.005</td></tr><tr><td>Univariate, mutation burden (per five units)<sup>&#8225;&#167;</sup></td><td colspan="2">0.98</td><td>0.97, 1.00</td><td>NS (0.072)</td><td colspan="2">0.99</td><td colspan="5">0.97, 1.01</td><td>NS (0.4)</td></tr><tr><td>Meta-analysis, tumor CNA burden (per 5%)<sup>#</sup></td><td colspan="2">1.04</td><td>1.02, 1.05</td><td>&lt;0.0001**</td><td colspan="2">1.02</td><td colspan="5">1.01, 1.04</td><td>0.005<sup>&#8224;&#8224;</sup></td></tr><tr><td>Meta-analysis, tumor CNA burden (per 5%), excluding outlier cancer types<sup>&#8225;&#8225;</sup></td><td colspan="2">1.05</td><td>1.03, 1.07</td><td>&lt;0.0001<sup>&#167;&#167;</sup></td><td colspan="2" valign="top">1.03</td><td colspan="5">1.01, 1.04</td><td>0.002<sup>##</sup></td></tr></tbody></table><table-wrap-foot><fn><p>*Prostate primary tumors: patient n&#160;=&#160;261 for all models except multivariable model with mutation burden, where n&#160;=&#160;227; event n&#160;=&#160;33; median follow-up time for survivors 40 (IQR 25,81) months.</p><p>&#8224;Prostate metastatic tumors: patient n&#160;=&#160;216 for all models except multivariable model with mutation burden, where n&#160;=&#160;205; event n&#160;=&#160;80; median follow-up time for survivors 59.5 (IQR 32, 129) months.</p></fn><fn><p>&#8225;Pan-cancer primary tumors, univariate models: patient n&#160;=&#160;6610, event n&#160;=&#160;1535, median follow-up time for survivors 24 (IQR 11, 61) months</p><p>&#167;Pan-cancer metastatic tumors, univariate models: patient n&#160;=&#160;4864, event n&#160;=&#160;1467, median follow-up time for survivors 51 (IQR 23, 109) months.</p></fn><fn><p>#Pan-cancer meta-analysis, among ten most prevalent cancer types: primary tumor patient n&#160;=&#160;4863, metastatic tumor patient n&#160;=&#160;3676. Estimates are based on overall fixed effects.</p><p>**p-value corresponds with test of effects size. Chi-square test for heterogeneity p-value=0.003.</p></fn><fn><p>&#8224;&#8224;p-value corresponds with test of effects size. Chi-square test for heterogeneity p-value=0.024.</p><p>&#8225;&#8225;Exclusion of cancer types to reduce heterogeneity: primary tumor patient n&#160;=&#160;3887, metastatic tumor patient n&#160;=&#160;3098. Estimates are based on overall fixed effects.</p></fn><fn><p>&#167;&#167;Excluding pancreatic and colorectal cancer, test of effects size p-value. Chi-square test for heterogeneity p-value=0.3.</p><p>##Excluding pancreatic and prostate cancer, test of effects size p-value. Chi-square test for heterogeneity p-value=0.8.</p></fn></table-wrap-foot></table-wrap>